Johnson & Johnson announced a more-than-$1 billion investment to build a cell therapy manufacturing facility in Pennsylvania, expanding the company’s clinical- and commercial-scale capacity for engineered cell therapies. The site is part of J&J’s broader strategy to secure internal supply chains for cell and gene medicines. The plant will support process development, scale-up and supply for advanced cellular products and reflects a trend of large pharma vertically integrating manufacturing for complex biologics. The investment aims to shorten time-to-market and reduce external capacity dependency. Manufacturers and CMOs should note the continued buildout of in‑house capacity by market leaders; this will influence partner demand dynamics and create more competition for skilled manufacturing personnel and CDMO capacity in the cell therapy space.